Skip to main content

Table 2 Administered regimens with and without ILD (n = 39)

From: Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer

Administered regimen

With ILD

Without ILD

EC only

0

1

EC followed by wPTX

0

9

dd EC only

3

0

dd EC followed by wPTX

2

9

EC followed by wPTX with HER

0

6

EC followed by triweekly docetaxel with HER

0

1

EC followed by wPTX with HER and PER

0

4

ddEC followed by wPTX with HER

0

1

ddEC followed by wPTX with HER and PER

0

3

  1. ILD interstitial lung disease, E epirubicin, C cyclophosphamide, wPTX weekly paclitaxel, dd dose dense, HER trastuzumab, PER pertuzumab